Candesartan cilexetil
Key facts
Invented name |
Blopress and associated names
|
Active substance |
Candesartan cilexetil
|
Therapeutic area |
Cardiovascular diseases
|
Decision number |
P/22/2009
|
PIP number |
Candesartan cilexetil
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Takeda Global Research and Development Centre (Europe) Ltd
E-mail: m.mantock@tgrd.com |
Decision type |
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan
|